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Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML)
currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently
reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competitive inhibitors of
cellular Bcr-Abl kinase activity that target the myristate binding site. Here, we used cell-based
structure-activityrelationshipstoguidetheoptimizationanddiversificationofligandsthatarecapable
of binding to the myristate binding site and rationalize the findings based upon an Abl-compound 1
cocrystal. We elucidate the structure-activity relationships required to obtain potent antiproliferative
activity against Bcr-Abl transformed cells and report the discovery of new compounds (5g, 5h, 6a, 14d,
and21j-I)thatdisplayimprovedpotencyorpharmacologicalproperties.Thisworkdemonstratesthata
variety of structures can effectively target the Bcr-Abl myristate binding site and provides new leads for
developing drugs that can target this binding site.
Introduction
Chronicmyelogenousleukemia(CML
a) isahematological
disorder caused by a chromosomal rearrangement that gen-
erates a fusion protein, Bcr-Abl, with deregulated tyrosine
kinaseactivity.
1Althoughclinicalremissionhasbeenachieved
with the ATP-binding site targeting drug imatinib, many
patientsrelapsebecauseofemergence ofclonesexpressing
inhibitor-resistant forms of Bcr-Abl.
2 To address these re-
lapses, two more potent ATP-site directed agents, nilotinib
3,4
and dasatinib,
5,6 have recently received clinical approval.
Althoughbothcompoundsinhibitmostofthemutationsthat
induce resistance to imatinib, neither compound is capable of
inhibiting the “gatekeeper”T315Imutation,which issituated
in the middle of the ATP-binding cleft.
7
Inanefforttofind newpharmacologicalmodalities ofBcr-
Ablinhibition,weperformedadifferentialcytotoxicityscreen
thatresultedintheidentificationof1,anon-ATPcompetitive
inhibitor of cellular Bcr-Abl activity.
8 A major advantage of
non-ATP competitive kinase inhibitors is that they can be
highlyselectiveforaparticularkinasebecausetheycanexploit
nonconserved kinase regulatory mechanisms. Indeed, 1 de-
monstrated exclusive cellular activity against Bcr-Abl trans-
formedcells(EC50=140 nM) anddid not inhibit the activity
of 40 other tyrosine kinases in cellular assays or the biochem-
icalactivityofapanelof80diversekinases.
8Compound1was
demonstrated to bind to the myristate binding site located
near the C-terminus of the Abl kinase domain using protein
crystallography and NMR spectroscopy.
9 Compound 2,
9 the
hydroxylethylamide analogue of 1, with improved pharma-
cologicalpropertiesisefficaciousinBcr-Abl-dependentxeno-
graft and bone marrow transplantation models against wild-
typeBcr-AblandiscapableofinhibitingT315IBcr-Ablwhen
used in combination with the ATP competitive inhibitor
nilotinib.Bindingof1or2tothemyristatebindingsiteinduces
changes to the conformational dynamics of the ATP-site as
revealed by hydrogen-deuterium exchange studies, but the
preciseconformationinducedbymyristate-sitebindingremains
to be elucidated.
Compound1 wasdevelopedbyiterativestructure-activity
guided optimization using Bcr-Abl transformed Ba/F3 cells.
Theoriginal“hit”compound,GNF-1(4a),
8wasdiscoveredby
screening a combinatorial library of 50000 heterocycles orig-
inallydesignedtotargettheATPbindingsite.Thelibrarywas
synthesizedonsolidphaseusingtheIRORInanokansystem.
10
The screen sought compounds that were differentially cyto-
toxic between murine 32D cells versus 32D cells transformed
with Bcr-Abl. Compounds 1 and 4a have a 4,6-disubstituted
pyrimidine core structure that has received some attention as
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an ATP-binding site directed scaffold
11,12 but has not been as
extensively investigated as the corresponding 2,4-disubstitut-
ed pyrimidines.
13,14 Here, we describe the structure-activity
relationshipsforthe4,6-disubsitutedpyrimidineclassofBcr-Abl
myristate binding site-targeted ligands. Using established med-
icinal chemistry approaches such as introduction of ring con-
straints to reduce entropic penalties upon ligand binding, we
havesuccessfullydiscoveredadditionalheterocyclicringsystems
suchasthieno[2,3-d]pyrimidines,pyrrolo[2,3-d]pyrimidines,and
pyrazolo[3,4-d]pyrimidines that can inhibit cellular Bcr-Abl
activity by binding to the myristate-binding site.
Results and Discussion
Synthesis. 4,6-Disubstituted pyrimidines were prepared
from 4,6-dichloropyrimidine by base-promoted amination
followedbypalladiummediatedcouplingwithboronicacids
or esters, anilines, or phenols (Scheme 1).
15
Further elaboration of the pyrimidine 6-substituent was
accomplished by alkylation, sulfonamide or amide-bond
formation. 2,4-Disubstituted pyrimidines, 2,6-disubstituted
pyrazines, 2,4-disubstituted triazines, and 3,6-disubstituted
pyridazineswerepreparedusingmethodologysimilartothat
of 4,6-disubstituted pyrimidines preparation as described in
the Supporting Information in order to explore similar core
structures to the 4,6-disubstituted pyrimidines. Thieno[2,3-
d]pyrimidines substituted at the 6-position were synthesized
in three steps by condensation of methyl 2-mercaptoacetate
with 4-chloro-6-(4-(trifluoromethoxy)phenylamino)pyrimidine-
5-carbaldehyde under basic conditions, followed sequen-
tially by ester hydrolysis and amide bond formation using
HATU (Scheme 2).
Pyrrolo[2,3-d]pyrimidines were prepared by N9 alkylation on
4-chloro-7H-pyrrolo[2,3-d]pyrimidinewithprimaryiodo-orbro-
moalkanesandsodiumhydride,followedbythermalsubstitution
of the 6-chloro group with the corresponding anilines. Further
modification of the N9-substituent was accomplished by ester
hydrolysis and amide bond formation using HATU (Scheme 3).
Scheme 1
a
aReagentsandconditions:(a)4-trifluoromethoxylaniline(1.1equiv),
DIEA(1.1equiv),EtOH,reflux;(b)primaryorsecondaryamine,DIEA,
2-BuOH, reflux; (c) substituted phenylboronic acid (1.0 equiv), Pd-
(PPh3)4 (5%), Na2CO3 (4.0 equiv), CH3CN/H2O (v/v = 1/1), reflux;
(d) amine, HATU, DIEA, DMF, room temp; (e) substituted pyrazole-
boronicacid (1.0equiv), Pd(PPh3)4 (5%),Na2CO3 (4.0equiv), CH3CN/
H2O (v/v = 1/1), reflux; (f) Cs2CO3,R 6Br (1.1 equiv); (g) heteroaro-
matic boronic acid (1.0 equiv), Pd(PPh3)4 (5%), Na2CO3 (4.0 equiv),
CH3CN/H2O (v/v = 1/1), reflux; (h) 2-morpholinoethanamine (1.0
equiv), DIEA(1.5 equiv),EtOH,reflux; (i) 4-(trifluoromethoxy)phenol,
NaH, dioxane, room temp to reflux.
Scheme 2
a
aReagents and conditions: (a) methyl 2-mercaptoacetate, K2CO3,
DMF,roomtempto90 C;(b) LiAlH4,0 C;(c)LiOH/THF;(d)primary
or secondary amine, HATU, DMF, room temp.
Scheme 3
a
aReagents and conditions: (a) primary iodo- or bromoalkane, NaH,
DMF,0 Ctoroomtemp;(b)4-(trifluoromethoxy)aniline,2-BuOH,120 C;
(c) methyl 3-bromopropanoate, NaH, THF; (d) 4-(trifluoromethoxy)-
aniline, 2-BuOH, 120  C; (e) Cs2CO3, THF/H2O; (f) R2NH2, HATU,
DIEA, DMF, room temp.
Scheme 4
a
aReagents and conditions: (a) RNHNH2,N a 2CO3, 2-BuOH, 60  C;
(b) NH2NH2, THF; (c) primary bromo- or chloroalkane, Cs2CO3 or
K2CO3, DMF.6936 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 Deng et al.
Pyrazolo[3,4-d]pyrimidines were prepared through two
different synthetic routes: either 4-chloro-6-(4-(trifluoro-
methoxy)phenylamino)pyrimidine-5-carbaldehyde was con-
densed with an appropriate alkylhydrazine or this condensa-
tionwasperformedusinghydrazinefollowedbyN1alkylation
with a primary iodo- or bromoalkane under cesium or potas-
sium carbonate (Scheme 4). The regioisomeric products were
subsequently separated by mass-triggered high-pressureliquid
chromatography.
Bcr-Abl Structure-Activity Relationships for 4,6-Disubsti-
tuted Pyrimidines. Following the identification of 4a as a
screening “hit” that specifically inhibited Bcr-Abl trans-
formed cells with an EC50 of 1 μM, a systematic evaluation
of the structural features necessary to impart activity as a
cellular Bcr-Abl inhibitor was investigated. We initiated our
investigation by replacing the morpholinoethylamino sub-
stituentlocatedatthepyrimidineC4-positionwitharangeof
functionalities including primary and secondary amines,
anilines, phenols, and various aromatic and heteroaromatic
substituents (Table 1). Compounds containing a direct aro-
matic linkage such as1, 5a, and5c displayed themost potent
activity, while alkylamine (4b and 4c) derivatized com-
pounds displayed reduced activity. The advantage of direct
aromatic linkage at the pyrimidine C4-position (1) is evident
by the loss of activity observed for the corresponding ether
(4e) and amine-linked (4f) derivatives. In the aryl series,
optimal activity was achieved with hydrogen bond donating
or accepting functionalities (CONR1R2,S O 2CH3,S O 2NHR,
Table 1. SAR of 4,6-Disubstituted Pyrimidine
aCytotoxicity (EC50, μM) on parental Ba/F3.
bAntiproliferative activity (EC50, μM) on wtBcr-Abl-Ba/F3.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6937
NH2)atthe3-or4-positionofthephenylringasshownby1,
2, 5a, and 5d-h. Substitution with a 2-carboxamide (5b)
resulted in an inactive compound presumably as a result
of steric hindrance or due to unfavorable torsional angle
between the pyrimidine and 4-phenyl substituent. We next
investigated additional analogues of 1 focusing on replace-
ments of the C4-benzamide substitutent. Replacements of
theamidewithsulfone(5e),primaryamine(5f),sulfonamide
(5g), and homologated amides (5i-k) all resulted in com-
pounds with cellular potency comparable to that of 1 and 5c
(Table 1). These results suggested that this position maybe
faces the solvent-exposed region of the enzyme and would
provide a good location for modulating the physical and
pharmacological properties of the compound. Indeed the
hydroxyethylamide analogue 2 displayed similar cellular
Bcr-Abl inhibitory activity as well as favorable pharma-
cokineticpropertiesandwaschosenforevaluationinmurine
leukemia models.
9
Wealsointroduced sulfonamide and “reverse” sulfonamide
at the para position of the C6-phenyl. The unsubstituted
sulfonamide 5g (EC50 = 120 nM) and reverse methylsulfo-
namide 5h (EC50 = 40 nM) were obtained with improved
inhibitoryactivity.Weinstalledavarietyofheterocyclic ring
systems at C4 and discovered that unsubstituted (6a) and
alkyl substituted pyrazoles (6b, 6c, and 6e) displayed super-
ior potency compared to 4a (Table 1). Introduction of 5,6-
fusedaromaticsystemstothepyrimidine4-positionwasalso
tolerated with potent activity being observed for indoles
attached via the indole 4- or 5-position (7a, 7b) and azain-
doles attached via the azaindole 4-position (7c).
In sharp contrast to the range of functionality that was
tolerated at the pyrimidine C4-position, very few replace-
ments to the 4-trifluoromethoxyaniline were tolerated at the
pyrimidine C6-position (Table 2). For example, replacement
of the aniline NH with an N-methyl substitution (8a)o r
oxygen(8d)ordirectphenylringconnection(8e)resultedina
complete loss of cellular activity, suggesting that this group
maybe responsible for a critical contact with the enzyme.
N-Methyl substitution was chosen as the modification to
prepare the negative control for both the affinity chromato-
graphy and NMR-binding studies.
8,9 Similarly, regioiso-
meric m-trifluoromethoxyanilines (8c)o rp-trifluoromethoxy-
lbenzylamino-substituted compounds (8g) were completely
inactive. To our surprise, replacement of the trifluoromethyl
group witha methyl groupalsoresulted in acomplete lossof
activity (8b). The only substitution that was tolerated at C6
was the conservative replacement of the trifluoromethoxy
with a trifluoromethyl group (8f).
We next investigated the consequences of varying the
positions of the nitrogens located on the central pyrimidine
core (Table 3). Here, we discovered a strict requirement for
the 4,6-pyrimidine; both of the 2,4-pyrimidine regioisomers
(9c and 9d), pyrazine (9e), pyridazine (9f), and triazine (9l)
were inactive. This result suggested that in the context of
compound4a,the4,6-substitutionpatternisstrictlyrequired
to maintain cellular Bcr-Abl inhibitory activity.
Wenextfocusedourattentiononusingstructure-activity
relationships to deduce the bioactive conformation of
improved leads such as 1. One interesting observation was
that the 4,6-disubstitution requirement for the central pyri-
midine was different from that of ATP-competitive kinase
inhibitors where in general the 2,4-pyrimidine is favored as a
motifthatbindstothekinasehingeregion.Thisisbelievedto
be a consequence of 2,4-pyrimidines being able to assume
the cis conformation with respect to the NH-C2 bond that is
requiredtoformabidentateH-bondtothekinasehingeregion.
Table 2. SAR of Pyrimidine C6-position
aCytotoxicity (EC50, μM) on parental Ba/F3.
bAntiproliferative activity (EC50, μM) on wtBcr-Abl-Ba/F3.6938 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 Deng et al.
For example, the classical ATP-competitive 2,4-pyrimidine
CDK inhibitors such as 3-[[4-[2-[(3-chlorophenyl)amino]-
pyrimidin-4-yl]pyridin-2-yl]amino]propan-1-ol (CGP60474)
bind to CDK2 hinge residues using a cis conformation.
16
Considering that 1 was not able to function as an ATP-
competitive Bcr-Abl inhibitor, this led us to speculate that
the requirement for the 4,6-pyrimidine scaffold reflected a
need for these compounds to adopt a “trans” conformation
to beactive ascellular Bcr-Abl inhibitors. To investigate this
hypothesis, we created a series of compounds that would be
structurallysimilarbutexhibitdifferentpreferencesforcisor
trans conformations due to potential steric interactions
betweenorthopositionofthep-trifluoromethoxyanilinering
and the pyrimidine C5 in the cis-conformation (Figure 1).
Biologicalevaluationoftheresultingcompoundsdemonstrated
that only the inhibitors with a preference for the trans-
conformation were able to inhibit cellular Bcr-Abl activity.
Reasoning that the enhanced cellular potency of com-
pound 5c might allow us to uncover subtleties regarding
SAR at C6 that would not be apparent in the less potent 4a,
we prepared further analogues at this position (Table 3). We
again observed that methylation of the aniline NH (9g)
resulted in a complete loss of cellular activity. Similar to
4a, substitution of the trifluoromethoxy group with fluoro
(9h) and methoxy (9i) groups resulted in a complete loss in
activity.Onlyremovaloftheoxygenofthetrifluoromethoxy
group (9j) and introduction of a meta nitrogen (9k) resulted
in inhibitors that retained some activity.
Structural Biology of the Myristate Binding Site. The
myristate binding site is a cylindrical shaped cavity located
Table 3. SAR of Central Pyrimidine Core
aCytotoxicity (EC50, μM) on parental Ba/F3.
bAntiproliferative activity (EC50, μM) on wtBcr-Abl-Ba/F3.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6939
at the C-terminus of the Abl kinase domain. Before the
availability of the 1-Abl cocrystal (PDB code 3K5V),
9 we
initially used the docking program Glide to compute poten-
tial binding conformations of 1 to Abl.
17 The lowest energy
pose places 1 in an extended trans conformation with the
4-trifluoromethoxyaniline pointed toward the bottom of the
pocket. With the exception of the positioning of the benza-
mide, the Glide generated binding conformation for 1 was
the same as in the subsequently determined crystal structure
andcouldbeusedtorationalizetheaforementionedstructure-
activity relationships. Specifically it explains the strict
requirement for 4-substitution of the trifluoromethoxy group
and the preference for 4,6- versus 2,4-disubstitution which
favors the extended trans-conformation of the pyrimidine
and the tolerance for diverse substitution at the pyrimidine
6-positions which point out toward the solvent exposed
region. In the cocrystal (Figure 2), a water molecule forms
a hydrogen bond bridge between the aniline NH and the
main chain carbonyls of A433 (Abl 1a numbering) and E462
in the myristate binding site. This observation can explain
the lossofpotencyobserved when theanilineNH is replaced
with oxygen (8d)o ra nN-methyl group (8a). Residues
making contact with 1 at the base of the pocket are L341
andA344fromRE,I432fromRF,V468fromRH,F493from
RI, and I502 from RI0. The surface in the central part of the
pocket is formed by A337 from RE, C464 and P465 from the
Figure 2. Cocrystal structure of 1 with Abl kinase (PDB entry 3K5V). (A) Binding conformation of 1 (cyan) in the myristate binding site of Abl
(sidechainsfromhelixREaregreen,RForange,RIdarkorange,R0Ired).Hydrogenbondstoawatermolecule(redsphere)areindicatedbydashed
yellow lines. (B) Solvent accessible surface of the myristate binding pocket colored as in panel A viewed from the mouth of the binding pocket.
Figure 1. SARforanaloguesof4aindicates thatatransconforma-
tion is favored.6940 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 Deng et al.
startofRH,A433fromRF,andV506fromRI0.Thefitinthis
region is quite snug, explaining the intolerance for substitu-
tion to the trifluoromethylphenyl ring. There are fewer
interactions at the mouth of the pocket (Y435 from RF,
E462 from the loop before RH, and L510 at the end of RI0),
which is caused by the flexibility and hence slightly weaker
electron densityofthebenzamidepart of1.Thisexplainsthe
diverse rangeoffunctionalitiesthatcan beincorporatedinto
this position.A mutagenesis screen resulted in the identifica-
tion of five mutations around the myristate binding pocket
(C464Y, P465S, V506L, F497L, E505K) that cause resis-
tance to 1 and 2.
9 On the basis of the crystal structure, these
would beexpectedtocauseresistancebecauseofdirect steric
hindrance to binding or more indirectly because of the
position of helix I.
Ring Constrained Analogues of 1. We were interested in
further optimizing the cellular potency of the 1 class of Bcr-
Ablkinaseinhibitorsandexploringtheirpotentialtotargeta
variety of Bcr-Abl mutants that are resistant to ATP-com-
petitive inhibitors such as imatinib, nilotinib, and dasatinib.
For example, 1 is active on wild-type Bcr-Abl, E255V, and
Y253H mutants but is inactive on the T315I “gatekeeper”
mutantwhichhasproventobethemostrecalcitranttoinhibit.
To create further analogues of 1, we designed conformation-
allyconstrainedcompoundsbyintroducingfusedringsystems
(Figure 3). We initially explored the potential to fuse a five-
membered ring between the pyrimidine 5 and 6 positions to
create four classes of 6,5-fused heterocyclic ring systems:
6-substituted thieno[2,3-d]pyrimidines, 7-substituted pyrrolo-
[2,3-d]pyrimidines, and 1- and 2-substituted pyrazolo[3,4-
d]pyrimidines (Figure 3, constraint A). Collectively these scaf-
folds provide the possibility of directing one or two substitu-
ents from various positions of the five-membered ring system.
Substitution of the 6-position of the thieno[2,3-d]-
pyrimidines scaffold with a variety of carboxamides (Table 4)
Figure 3. Rationale for the evolution of structures from screening
hit 4a to 1, 2, and a variety of 6,5-fused heterocyclic ring systems.
Table 4. SAR of the Thieno[2,3-d]pyrimidines
aCytotoxicity (EC50, μM) on parental Ba/F3.
bAntiproliferative activity (EC50, μM) on wtBcr-Abl-Ba/F3.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6941
resultedintheidentificationofseveralcompoundswithEC50
valuesofapproximate1μMfortheinhibitionofcellularBcr-
Abl activity. The optimal compound in this series was
obtained by introduction of an N-methylpiperazine as
exemplified by compound 14d, which possessed an EC50 of
48 nM (Table 4). Interestingly this compound was approxi-
mately 10-fold more potent than the compound lacking
N-methylation (14c).
Preparation ofsix7-substitutedpyrrolo[2,3-d]pyrimidines
resulted in the optimal activity being identified from mor-
pholinoethyl(16c)substituent(Table5).Inhibitor16c,which
can be viewed as the ring fused analogue of 4a, is approxi-
mately equipotent to 4a.
We prepared a 20-membered focused library for 1- and
2-substituted pyrazolo[3,4-d]pyrimidines (Table 6). The
potency of the 1- or 2-substituted regioisomers was typically
similar with the biggest difference being observed for the
benzyl substituted compound 21f where the 2-substituted
compound is completely inactive (Table 6). A variety of
compoundswerediscoveredthatpossessedpotencycompar-
able to that of 1 such as alkyl substituted inhibitors 21a-f.
The most potent inhibitor in this series was tert-butyl sub-
stitutedcompound21j-IwhichpossessedanEC50of160nM,
even though compound 21j-I inhibited the growth of
untransformed Ba/F3 cells to some degree (EC50 =7 . 3μM),
suggesting additional cellular targets for this compound
class.
Biological Profiling of Select 1 Analogues. We selected
eight compounds that possessed optimal Bcr-Abl potency
andthatwererepresentativeofthedifferent structureclasses
and tested them in a panel of biochemical and cellular assays
to assess their mechanism of action relative to 1. Because
several of the compounds are structurally similar to ATP-
competitive kinase inhibitors, we sought to investigate their
potential to interact with diverse kinase ATP-binding sites.
This was assessed using KINOMEscan (Ambit Biosciences,
San Diego, CA), a high-throughput method for screening
kinase inhibitors against a panel of 353 kinases.
18 Com-
pounds were screened at 10 μM; none of the compounds
displayed the ability to target the ATP-binding site of any
kinases in the panel. In order to demonstrate that these new
compounds indeed function as myristate-site ligands, we
tested their ability to compete for binding to Abl kinase
domain with a fluorescein-linked 1 analogue using a fluore-
scence polarization assay (Figure 4).
19 By performing this
assay at a range of inhibitor concentrations, we could measure
a dissociation constant (Kd) for each compound (Figure 4B).
We demonstrated that all compounds were competitive with
respect to 1-FITC for binding to the myristate binding site.
In addition, there was a good correlation between the EC50
for inhibition of cellular Bcr-Abl activity and Kd determined
using the fluorescence polarization assay (Figure 4C). This
provides evidence that changes in cellular potency that we
observe for these analogues are likely to reflect the affinity
withwhichtheybindtothemyristatebindingsiteratherthan
differences in cell penetration and accumulation. All analo-
gueswerealsounabletoinhibittheproliferationoftwopoint
mutants located in the myristate binding site (A337N and
A344L) that we had previously
8 demonstrated induced resis-
tanceto1.Thisprovidesevidencethatthecellularsiteofaction
of these analogues is also the Bcr-Abl myristate binding site.
Cumulatively, these results are consistent with these new
compounds exploiting the same mechanism of action as 1 to
inhibit Bcr-Abl dependent proliferation.
To ascertain the ability of these compounds to inhibit
clinically relevant Bcr-Abl mutants, they were tested against
T315I, E255K, and E505K mutants (Table 7).
20
The results revealed that most of the compounds have
submicromolar potency against wild-type and E255K with
the exception of 14d, 16c, and 21a-I. As expected, all the
compounds are inactive on gate-keeper mutant T315I and
myristate bind site mutant E505K. As we have previously
reported that 2 is capable of synergizing with ATP-compe-
titive inhibitors such as nilotinib to inhibit the proliferation
of T315I Bcr-Abl, we tested the potential of selected com-
pounds to exhibit synergistic inhibition with the type-I ATP
competitive inhibitor dasatinib (Table 8).
9 Interestingly the
compoundsexhibitedconsiderabledifferencesintheirability
Table 5. SAR of 7-Substituted Pyrrolo[2,3-d]pyrimidines
aCytotoxicity (EC50, μM) on parental Ba/F3.
bAntiproliferative activity (EC50, μM) on wtBcr-Abl-Ba/F3.6942 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 Deng et al.
to combine with dasatinib to inhibit T315I Bcr-Abl-depen-
dent proliferation. In addition, the calculated combination
indices (CI)
21 did not correlate with the ability of the com-
pounds to inhibit wild-type Bcr-Abl as single agents. Under-
standingthemechanisticbasisforthiswillrequireastructure
of Abl ligated with both dasatinib and a myristate-site ligand.
Conclusions
WehavepresentedacomprehensiveexplorationofBcr-Abl
myristate targeted ligands derived from 1/4a lead structures.
We demonstrate that the 4-trifluoromethoxyaniline is an
obligate structural feature for achieving submicromolar
potencyasacellularBcr-Ablinhibitorbutthatthepyrimidine
ring can be elaborated to include a variety of other hetero-
cyclic ring systems. We identify several analogues with 5- to
10-fold improved potency against wild-type and some Bcr-
Abl mutants such as E255K relative to 1. The most potent
myristate-site targeted inhibitors we have discovered to date
are sulfonamide 5g (EC50 = 120 nM), reverse methylsulfo-
namide 5h(EC50= 40nM), pyrazole-compound6a (EC50=
90 nM), 6-methylpiperazine amide thieno[2,3-d]pyrimidine
14d (EC50 = 48 nM), and pyrazolo[3,4-d]pyrimidines 21j-I
(EC50 = 160 nM), which are still less potent than highly
optimizedATP-competitiveligandssuchasdasatinib(EC50=
20 nM) and nilotinib (EC50 = 40 nM) under our assay con-
ditions. We demonstrate that a good correlation exists
betweenthebindingaffinityforthemyristatebindingsiteand
potency as a cellular Bcr-Abl inhibitor. Although further
optimization of the binding affinity 1 class of ligand may be
possible, because the mechanism of inhibition of Bcr-Abl is
allosteric, it maybe limited bysomething other than myristate
ligand affinity. We have also discovered that different myri-
state ligands display a differential ability to synergize with
dasatinib to inhibit the T315I Bcr-Abl mutant. For example,
potentwild-typeinhibitor6a(EC50=90nM)doesnotexhibit
synergy with dasatinib against T315I Bcr-Abl while the less
potent inhibitor 21a-I does. The mechanistic basis for this
effect is currently under investigation. The work presented
here demonstrates that a variety of promising lead com-
pounds can be identified that bind potently to the myristate
bindingsiteandinhibitcellularBcr-Ablactivity.Theabilityof
these compounds to synergize with ATP-competitive inhibi-
tors to inhibit the growth of cells transformed with Bcr-Abl
mutants and likely to prevent or delay the emergence of
resistance mutations should encourage this new therapeutic
Table 6. SAR of 1- and 2-Substituted Pyrazolo[3,4-d]pyrimidines
aCytotoxicity (EC50, μM) on parental Ba/F3.
bAntiproliferative activity (EC50, μM) on wtBcr-Abl-Ba/F3.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6943
modalitytobeexploredclinically.Asavarietyofkinasessuch
as PKC,
22 mTor,
23 Arg,
24 and SK1
25 and Akt
26 have been
demonstratedtoberegulatedthroughinter-orintramolecular
interactions with lipids, screening this compound collection
for allosteric inhibitors of lipid binding sites may prove
valuable.
Experimental Section
Chemistry. Unless otherwise noted, reagents and solvents
wereobtainedfromcommercialsuppliersandwereusedwithout
furtherpurification.
1HNMRspectrawererecordedat400MHz
(Bruker XWIN-NMR) or 600 MHz (Varian AS600), and
chemical shifts are reported in parts per million (ppm, δ) down-
field from tetramethylsilane (TMS). Coupling constants (J) are
reportedinHz.Spinmultiplicitiesaredescribedass(singlet),brs
(broad singlet), t (triplet), q (quartet), and m (multiplet). Mass
spectra were obtained on a Waters Micromass ZQ instrument.
Preparative HPLC was performed on a Waters Symmetry C18
column (19 mm   50 mm, 5 μM) using a gradient of 5-95%
acetonitrile in water containing 0.05% trifluoacetic acid (TFA)
over8min(10minruntime)ataflowrateof30mL/min.Purities
of assayed compounds were in all cases greater than 95%, as
determined by reverse-phase HPLC analysis.
Cell Culture and Cell Proliferation Assay. Ba/F3.p210 cells
were obtained by transfecting the IL-3-dependent murine
hematopoietic Ba/F3 cell line with a pEYK vector containing
p210BCR-ABL and Bcr-Abl mutations.
9,27 All cell lines were
cultured with 5% CO2 at 37  C in RPMI 1640 (Invitrogen) with
10% fetal bovine serum (FBS) and supplemented with 1%
L-glutamine. Parental Ba/F3 cells were similarly cultured with
10% WEHI-conditioned medium as a source of IL-3. Trans-
fectedcelllineswereculturedinmediasupplementedwith25μg/
mL zeocin. The 48 h cell proliferation studies were obtained
using theCellTiter-Glo assay(Promega) as previous described.
8
For drug combination studies, compounds were added
simultaneously at fixed ratios to cells, and cell viability was
determined by CellTiter-Glo assay (Promega) and expressed as
a function of growth affected (FA) drug-treated cells versus
control cells. Synergy was assessed by Calcusyn software
(Biosoft; Ferguson, MO, and Cambridge, U.K.), using the
Chou-Talalay method.
21 The combination index CI indicates
the strength of the synergy effect. Values less than 1 indicate
synergy, whereas values greater than 1 indicate antagonism.
Procedure for the Synthesis of N
4-(3-Morpholinopropyl)-N
6-
(4-(trifluoromethoxy)phenyl)pyrimidine-4,6-diamine (4b). To a
stirredsolutionof4,6-dichloro-pyrimidine(298.0mg,2.0mmol)
and4-trifluoromethoxyaniline(0.27mL,2.0mmol)in1.0mLof
EtOH was added DIEA (0.35 mL, 2.0 mmol). The reaction
mixture was stirred for 16 h at 80  C. Then the mixture was
concentrated and purified by silica gel column chromatography
to give the title compound 3 (521 mg, 90% yield). MS (ESI) m/z
290 (M þ H)
þ.
Toastirredsolutionofcompound3(29mg,0.10mmol)and
DIEA (35 μL, 0.20 mmol) in 1 mL of sec-BuOH was added
3-morpholinopropan-1-amine (29 μL, 0.20 mmol) at room
Figure 4. Dissociation constants (Kd) for a series of 1 analogues correlate with EC50 for inhibition of cellular Bcr-Abl activity. (A) Chemical
structure of 1-FITC tracer. (B) Dissociation constants (Kd) were determined using a fluorescence polarization competition binding assay to
Abl kinase domain with 1 analogues and fluorescein-linked 1 tracer. (C) Graph showing the correlation between compound dissociation
constant (Kd) and its cellular EC50 value for Bcr-Abl inhibition.
Table7. CellularActivityofSelect1AnaloguesagainstSomeClinically
Relevant Bcr-Abl Mutants
a
cellular EC50 (μM)
compd Wt-Bcr-Abl T315I E255K E505K Wt-Ba/F3
1 0.14 >10 0.60 >10 >10
2 0.43 >10 0.58 >10 >10
5g 0.12 >10 0.31 >10 >10
5h 0.04 >10 0.36 >10 >10
6a 0.09 >10 0.52 >10 >10
14d 0.05 >10 1.33 >10 >10
16c 0.38 >10 1.22 >10 >10
21a-I 0.25 >10 1.61 >10 >10
21j-I 0.16 >10 0.50 >10 >10
aAntiproliferative activity (EC50, μM) on select cell lines.
Table8. SynergisticEffectofSelect1AnalogueswithDasatinibagainst
T315I Mutant
CI value at
compd (ratio ED50 ED75 ED90 Dm r
dasatinib þ 5g (1:1) 0.4973 0.27007 0.48539 0.99256 0.94707
dasatinib þ 5h (1:1) 0.61781 0.38123 0.25814 0.90849 0.55459
dasatinib þ 6a (1:1) 0.54179 0.71033 0.95607 0.77202 0.94716
dasatinib þ 14c (1:1) 0.75652 0.70471 0.65645 0.41015 0.90394
dasatinib þ 14d (1:1) 0.30119 0.13126 0.11157 0.96888 0.50907
dasatinib þ 20a (1:1) 0.40752 0.35515 0.47618 0.96398 2.23613
dasatinib þ 21a-I (1:1) 0.70277 0.36185 0.48377 1.30175 0.766796944 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 Deng et al.
temperature. Then the resulting mixture was stirred at 120  C.
After the reaction was complete as monitored by reverse phase
analytical liquid chromatography-electrospray mass spectro-
metry (LC-MS), the solvent was removed and the title com-
pound was purified by reverse-phase preparative HPLC using
a water (0.05% TFA)/acetonitrile (0.05% TFA) gradient to
afford the title compound 4b as the TFA salt (30 mg, 59%).
1H
NMR (600 MHz, CD3OD) δ 8.26 (s, 1H), 7.50 (d, J = 7.2 Hz,
2H), 7.34 (d, J = 8.4 Hz, 2H), 5.92 (s, 1H), 4.03 (brs, 2H), 3.79
(brs, 2H), 3.47 (brs, 4H), 3.26-3.23 (m, 2H), 3.14 (brs, 2H),
2.12-2.08 (m, 2H). MS (ESI) m/z 398 (M þ H)
þ. HRMS (ESI)
calcd for C18H22F3N5O2 397.1726, found 398.1797 (M þ H)
þ.
Procedure for the Synthesis of N-(2-Hydroxyethyl)-3-(6-(4-
(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide (2). A
mixture of 6-chloro-N-(4-(trifluoromethoxy)phenyl)pyrimidin-
4-amine (200 mg, 0.69 mmol), 3-carboxyphenylboronic acid
(115 mg, 0.69 mmol), Pd(PPh3)4 (40 mg, 0.034 mmol), and
sodium carbonate (292 mg, 2.76 mmol) in acetonitrile/water
(v/v = 1/1, 10 mL) was heated to 90  C under an argon atmo-
sphere. After refluxing for 8 h, the hot reaction mixture was
filtered.Thefiltratewascooledtoroomtemperatureandtreated
with 6 N HCl (pH is around 4) to afford 3-(6-(4-(trifluoro-
methoxy)phenylamino)pyrimidin-4-yl)benzoic acid as a pale
yellow precipitate, which was collected and washed with water
and air-dried to give 202 mg (78% yield) of the title com-
pound. MS (ESI) m/z 376 (M þ H)
þ.
To a solution of 3-(6-(4-(trifluoromethoxy)phenylamino)-
pyrimidin-4-yl)benzoic acid (56.3 mg, 0.15 mmol), ethanol-
amine (27 μL, 0.45 mmol), and diisopropylethylamine (53 μL,
0.30mmol) in1.50mLofdimethylformamidewasadded1-hydroxy-
1H-benzotriazole “HOBt” (30 mg, 0.22 mmol) at room tempera-
ture. Then the mixture was cooled to 0  C and (3-(dimethyla-
mino)propyl)ethylcarbodiimide hydrochloride“EDCI”(52mg,
0.27 mmol) was added. And the mixture was warmed to room
temperature gradually. After the reaction was completed, as
monitored by LC-MS, the reaction mixture was poured into
water and extracted with ethyl acetate. The organic layer was
washedwithbrine,driedoveranhydrousNa2SO4,concentrated,
andpurifiedbysilicagelcolumnchromatographytoafford2(50
mg,80%yield).
1HNMR(600MHz,DMSO-d6),δ9.92(s,1H),
8.75 (s, 1H), 8.60 (t, J = 5.4 Hz, 1H), 8.51 (s, 1H), 8.17 (d, J =
7.8 Hz, 1H), 7.98 (d, J = 7.2 Hz, 1H), 7.84 (d, J = 9.0 Hz, 2H),
7.61 (t, J = 7.8 Hz, 1H), 7.34 (d, J = 9.0 Hz, 2H), 7.33 (s, 1H),
4.73(t,J=5.4Hz,1H),3.54(t,J=6.0Hz,2H),3.36(t,J=6.0
Hz, 2H). MS (ESI) m/z 419 (M þ H)
þ.
Procedure for Synthesis of Methyl 4-(4-(Trifluoromethoxy)-
phenylamino)thieno[2,3-d]pyrimidine-6-carboxylate (11). To a
stirred solution of 4,6-dichloropyrimidine-5-carbaldehyde (1.0 g,
5.65mmol)in10mLofTHFwasadded4-trifluoromethoxyani-
line (0.72 mL, 5.36 mmol) at -10  C. After 10 min, the mixture
was stirred at room temperature for 5 h. Then the mixture was
diluted by ethyl acetate and filtered through Celite. The filtrate
wasconcentratedandpurifiedbysilicagelcolumnchromatography
to give compound 10 (1.13 g, 63% yield). MS m/z 318 (M þ H)
þ.
4-Chloro-6-(4-trifluoromethoxyphenylamino)pyrimidine-5-
carbaldehyde10(500mg,1.57mmol)inDMF(2mL)wasadded
toasuspensionofK2CO3(620mg,4.5mmol)inDMF(1mL)at
room temperature. After the mixture was stirred for 30 min,
methyl thioglucolate (210 mg, 1.9 mmol) was added slowly to
the reaction mixture. The resulting mixture was heated at 90  C
for 1 h. The reaction mixture was then cooled at room tempera-
ture and poured into ice-water. The precipitate was collected
and dried to afford the title compound 11 (400 mg, 69% yield).
1HNMR(600MHz,CDCl3)δ8.64(s,1H),8.16(s,1H),7.78(d,
J = 9.0 Hz, 2H), 7.25 (d, J = 9.0 Hz, 2H), 3.92 (s, 3H). MS m/z
370 (M þ H)
þ.
Procedure for the Synthesis of N-(2-Hydroxyethyl)-4-(4-(tri-
fluoromethoxy)phenylamino)thieno[2,3-d]pyrimidine-6-carboxamide
(14a). A mixture of methyl 4-(4-(trifluoromethoxy)phenylamino)-
thieno[2,3-d]pyrimidine-6-carboxylate (152 mg, 0.41 mmol) and
LiOH(25.5mg,1.07mmol) wasdissolvedinTHF(4mL) andH2O
(1 mL). The mixture was stirred at 60  C for 3 h. Acidification with
acetic acid resulted in a brown solid which was collected by
filtration. Compound 13 w a st h e nd r i e di nv a c u oa n du s e df o rt h e
next step without any further purification (115 mg, 79% yield).
1H
NMR(400MHz,DMSO-d6)δ10.13(s,1H),8.97(brs,1H),8.61(s,
1H), 8.00 (d, J = 9.2 Hz, 2H), 7.42 (d, J = 9.2 Hz, 2H). MS (ESI)
m/z 356 (M þ H)
þ.
4-(4-(Trifluoromethoxy)phenylamino)thieno[2,3-d]pyrimidine-
6-carboxylic acid (30 mg, 0.08 mmol) was mixed with DIEA
(30 μL, 0.172 mmol) and HATU (39 mg, 0.1 mmol) in 2 mL of
DMFatroomtemperature.2-Aminoethanol(6.1mg,0.1mmol)
wasaddedtothereaction mixture0.5hlater.After beingstirred
at room temperature for 2 h, the reaction mixture was concen-
trated and purified by preparative HPLC to afford the title
compound 14a as a TFAsalt (25 mg, 61% yield).
1H NMR (400
MHz, DMSO-d6) δ 10.10 (s, 1H), 9.26 (s, 1H), 8.82 (s, 1H), 8.21
(d,J=8.8Hz,2H),7.85(d,J=8.8Hz,2H),7.34(s,1H),3.02(t,
J=6.4Hz,2H),2.65(t,J=6.4Hz,2H).MSm/z399(MþH)
þ.
Procedure for Synthesis of N-(4-(Trifluoromethoxy)phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-amine (16a). To a stirred solution
of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (46.1 mg, 0.3 mmol)
and DIEA (78 μL, 0.45 mmol) in 2.0 mL of 2-BuOH was added
4-trifluoromethoxyaniline (79.7 mg, 0.45 mmol) at room tem-
perature. Then the mixture was heated to 120  C. After the
reaction was complete, as monitored by LC-MS, the solvent
was removed and purified by preparative HPLC to afford the
title compound 16a (66.6 mg, 60% yield).
1H NMR (400 MHz,
DMSO-d6)δ11.42(s,1H),9.58(s,1H),8.52(s,1H),7.76(d,J=
9.2 Hz, 2H), 7.24 (d, J = 9.2 Hz, 2H), 7.39 (d, J = 6.2 Hz, 1H),
6.52 (dd, J = 3.2, 1.6 Hz, 1H). MS (ESI) m/z 295 (M þ H)
þ.
Procedure for Synthesis of N-(3-Methoxypropyl)-3-(4-(4-
(trifluoromethoxy)phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-
propanamide (20a). To a stirred solution of 4-chloro-7H-pyrrolo-
[2,3-d]pyrimidine (1.0 g, 6.51 mmol) in DMF (30 mL) was added
NaH (60% in mineral oil) (391 mg, 9.76 mmol) at 0  C. After the
mixture was stirred for 30 min at room temperature, methyl
3-bromopropanoate (1.20 g, 7.18 mmol) was added and the
resulting mixture was stirred for 16 h at 40  C. Then the reaction
was quenched with saturated NH4Cl solution and extracted with
ethyl acetate. The organic extracts were washed with brine, dried
overNa2SO4,andconcentrated.Theresiduewaspurifiedbysilica
gel column chromatography to afford compound 17 (1.2 g, 77%
yield). MS m/z 240 (M þ H)
þ.
To a solution of 3-(4-chloro-pyrrolo[2,3-d]pyrimidin-7-yl)-
propionic acid methyl ester (100 mg, 0.42 mmol) and DIEA
(0.11 mL, 0.63 mmol) in sec-BuOH (3 mL) was added 4-tri-
fluoromethoxyaniline (80 mg, 0.45 mmol). The resulting mixture
wasstirredat120 Cfor2h.Thenthemixturewasconcentrated
and purified by silica gel column chromatography to afford
compound 18 (87.5 mg, 55% yield). MS m/z 381 (M þ H)
þ.
Toasolutionof3-[4-(4-trifluoromethoxyphenylamino)pyrrolo-
[2,3-d]pyrimidin-7-yl]propionic acid methyl ester (87.5 mg, 0.22
mmol) in 5 mL of mixed solvent THF/H2O (v/v = 3/1)) was
added Cs2CO3 (78 mg, 0.40 mmol). The resulting mixture was
stirred at 80  C for 2 h. The mixture was concentrated and
neutralized with acetic acid. The solid was filtered and dried to
yield compound 19 as a brown solid (62 mg, 77%). MS m/z 367
(M þ H)
þ.
3-[4-(4-Trifluoromethoxyphenylamino)pyrrolo[2,3-d]pyrimidin-
7-yl]propionic acid (25 mg, 0.068 mmol) was mixed with DIEA
(0.030 mL, 0.172 mmol) and HATU (28.5 mg, 0.075 mmol) in
1.0 mL of DMF at room temperature. 3-Methoxypropan-1-
amine(12.1mg,0.14mmol)wasaddedintothereactionmixture
0.5 h later. After being stirred at room temperature for 2 h, the
mixture was concentrated and purified by preparative HPLC to
afford the title compound 20a (17.8 mg, 60% yield).
1H NMR
(600 MHz, CDCl3) δ 11.53 (s, 1H), 8.29 (s, 1H), 7.44 (d, J = 8.4
Hz, 2H),7.34(d,J=8.4Hz,2H),7.12(d,J=3.0Hz,1H),6.23
(s, 1H), 5.46 (d, J = 2.4 Hz, 1H), 4.56 (t, J = 6.0 Hz, 4H), 3.43Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6945
(t, J = 6.0 Hz, 2H), 3.30 (s, 3H), 2.72 (t, J = 6.0 Hz, 2H), 1.70
(quintet, J = 6.0 Hz, 2H). MS (ESI) m/z 438 (M þ H)
þ.
Procedure for Synthesis of 2-(4-(4-(Trifluoromethoxy)pheny-
lamino)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)ethanol (21a-I) and
2-(4-(4-(Trifluoromethoxy)phenylamino)-2H-pyrazolo[3,4-d]pyri-
midin-2-yl)ethanol (21a-II).
28 To a solution of 4-chloro-6-(4-
trifluoromethoxyphenylamino)pyrimidine-5-carbaldehyde (50 mg,
0.16 mmol) in 2.0 mL of sec-BuOH was added Na2CO3 (30 mg,
0.28 mmol) and(2-hydroxyethyl)hydrazine (20 mg,0.26 mmol).
The mixture was stirred at 60  C for 8 h. The reaction mixture
was partitioned in 50 mL of water and 50 mL of ethyl acetate.
The aqueous layer was extracted with ethyl acetate three times.
The combined organic extracts were washed with brine, dried
over anhydrous Na2SO4, and concentrated. The crude product
was purified by silica gel column chromatography to give title
compounds 21a-I (20 mg) and 21a-II (5.0 mg).
21a-I:
1HNMR(400MHz,DMSO-d6)δ10.25(s,1H),8.45(s,
1H), 8.32 (s, 1H), 7.98 (d, J = 9.6 Hz, 2H), 7.41 (d, J = 9.6 Hz,
2H),4.40(t,J=6.0Hz,2H),3.83(t,J=6.0Hz,2H).MS(ESI)
m/z 340 (M þ H)
þ.
21a-II:
1H NMR (400 MHz, DMSO-d6) δ 10.75 (s, 1H), 8.68
(s, 1H), 8.57 (s, 1H), 7.97 (d, J = 9.6 Hz, 2H), 7.45 (d, J = 9.6
Hz, 2H), 4.41 (t, J = 6.0 Hz, 2H), 3.85 (t, J = 6.0 Hz, 2H). MS
(ESI) m/z 340 (M þ H)
þ.
Procedure for Synthesis of 1-(Pyridin-3-ylmethyl)-N-(4-(trifluo-
romethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (21g-I)
and 2-(Pyridin-3-ylmethyl)-N-(4-(trifluoromethoxy)phenyl)-2H-
pyrazolo[3,4-d]pyrimidin-4-amine (21g-II). To a stirred solution
of N-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-
4-amine (60 mg, 0.2 mmol) in 3.0 mL of DMF was added NaH
(60%inmineraloil)(32mg,0.8mmol)at0 C.Afterthemixture
was stirred for 1 h, 3-(bromomethyl)pyridine hydrobromide (48
mg, 0.19 mmol) was added. The resulting mixture was warmed
to room temperature gradually. After the reaction was com-
plete, as monitored by LC-MS, the mixture was poured into
ice-water and extracted with ethyl acetate. The combined
organic layers were washed with brine, dried over anhydrous
Na2SO4, and concentrated. The crude product was purified by
preparative TLC to give the title compounds.
21g-I:
1H NMR (600 MHz, CD3OD) δ 8.54 (s, 1H), 8.44 (d,
J = 4.8 Hz, 1H), 8.43 (s, 1H), 8.18 (brs, 1H), 7.89 (d, J =9 . 0H z ,
2H), 7.77 (dt, J=1 . 8 ,7 . 8H z ,1 H ),7 . 3 8(d d ,J=4 . 8 ,7 . 8H z ,1 H ),
7.28(d,J=8.4Hz,2H),5.64(s,2H).MS(ESI)m/z387(MþH)
þ.
21g-II:
1H NMR (600 MHz, CD3OD) δ 8.62 (d, J = 1.8 Hz,
1H), 8.52 (dd, J = 1.2, 4.8 Hz, 1H), 8.47 (brs, 1H), 8.38 (s, 1H),
7.90 (d, J = 8.4 Hz, 2H), 7.86 (dt, J = 1.8, 7.8 Hz, 1H), 7.45
(ddd, J =0.6,4.8, 7.2Hz, 1H),7.28(d, J= 8.4Hz, 2H),5.68(s,
2H). MS (ESI) m/z 387 (M þ H)
þ.
Fluorescence Polarization Assay. Abl kinases were prepared
as previous described,
9 and fluorescent-labeled 1 compound (1-
FITC) was used.
9
Fluorescence polarization assays of the competitive binding
of various concentrations of 1 analogues and fixed concentra-
tion of 50 nM 1-FITC to Abl were performed in the buffer
20 mMTris-HCl, pH 8.0,150mMNaCl in384-well platewith a
total reaction volume of 40 μL. The samples were incubated at
room temperature for 1 h, and the fluorescence polarization
(FP) was then measured using a SpectraMax M5 microplate
reader (Molecular Devices) equipped with a 530 nm emission
filter anda 490 nm excitation filter. FPvalues were converted to
percentage inhibition using the equation
I% ¼
P0 -P
P0 -P100
  100
where P0 is the FP value at 0%, P100 is the FP value when 100%
ofthe1-FITChasbeencompetitivelydisplacedfromthekinase
and 1-FITC complex, and P is the experimental FP value at
each concentration of the competing 1 analogues being tested.
The percentage inhibition versus competitor concentration
curves were analyzed by nonlinear least-squares curve fitting,
and the concentration of competing ligand required to displace
half of the bound 1-FITC ligand was determined (IC50).
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